Alkermes plc (ALKS)
Develops psychiatric and addiction medications delivered through injectable and oral formats.
$50.50-0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+90.2%
The outlook
ALKS is trading at $50.50 with analyst consensus leaning Buy, supported by price sitting above both its 50- and 200-day moving averages. The stock sits near the upper end of its 52-week range, and the average analyst target sits roughly 9% above the current price.
What’s behind the score
Analyst consensusBuy — 1.7 avg of 17 analysts
Price trendAbove its 50- & 200-day averages
52-week range83% of the way from its 52-week low to high
Price targetAvg target +9% vs current price
Analyst price target
~12-month · 17 analysts$54.88average target+8.7% vs now
Now $50.50
Low $38.00High $65.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.42B
52-wk high
$55.67
52-wk low
$25.17
50-day avg
$46.77
200-day avg
$35.14
Trailing P/E
56.1